Arrowhead Research | ARWR - Loan Capital


Arrowhead Research reported $538.1M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Anika Therapeutics USD 25M 25M Sep/2020
Arrowhead Research USD 538.1M 323.22M Dec/2025
Heron Therapeutics USD 140.64M 975K Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Ligand Pharmaceuticals USD 445.49M 445.44M Sep/2025
Merck USD 39.97B 6B Sep/2025
Moderna USD 610M 584M Dec/2025
Nektar Therapeutics USD 107.51M 10.35M Jun/2024
Novartis USD 29.59B 5.35B Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
TG Therapeutics USD 245.64M 305K Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025
Xencor USD 76.48M 11.29M Dec/2025